See the latest news and media coverage for Teva. We track all announcements, press releases, and industry mentions in real time, all in one place.
Innovative biopharmaceutical company with a generics business
tevapharm.comLast updated
In short: Teva achieved investment-grade status, advanced its Pivot to Growth strategy, and secured multiple FDA approvals.
This acquisition expands Teva's neuroscience pipeline and supports its Pivot to Growth strategy. The deal involves upfront and contingent payments totaling up to $125 million.
Duvakitug maintained long-term efficacy in ulcerative colitis and Crohn's disease patients over 44 weeks with a consistent safety profile.
The company held a conference call on October 9, 2026, to discuss the regulatory approval of the long-acting injectable antipsychotic.
Teva and Samsung Bioepis agree to develop up to six biosimilar candidates in the US, Europe, and Canada. Teva handles commercialization while Samsung Bioepis manages development and manufacturing.
BXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I...
Teva Pharmaceuticals and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension (LTE) study (clinical trial identifier: NCT05668013) in patients with...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
The share price of Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) jumped by 4.7% on a larger than usual volume on the New York Stock...
Track Teva and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Teva and other trending companies.
